Under the "if-converted" method, interest and issuance costs and potential common shares related to the Company's convertible senior notes were excluded in the computation of diluted per share amounts for the six months ended June 30, 2012 and 2011 because their effect would be anti-dilutive.
ONYX PHARMACEUTICALS, INC.RECONCILIATION OF GAAP TO NON-GAAP NET LOSS(In thousands, except per share amounts)(unaudited)Three Months EndedSix Months EndedJune 30, June 30, 2012201120122011(a) Adjustments to research and development expenses:Non-cash expense related to the unamortized balance of funding provided to S*BIO (4)
-$(12,666)Employee stock based compensation (3)
(2,715)(1,893)(4,648)(2,819)Total adjustment to research and development expenses
$ (2,715)$ (1,893)$ (4,648)$(15,485)(b) Adjustments to selling, general and administrative expenses:Employee stock based compensation (3)
$ (8,180)$ (6,451)$ (13,044)$(10,880)(c) Adjustments to contingent consideration expenseThe effects of contingent consideration expense are excluded due to the nature of this charge, which is related to the change in the fair value of the liability for contingent consideration in connection with the acquisition of Proteolix; such exclusion facilitates comparisons of Onyx's operating results to peer companies.
$(53,214)$ (5,755)$ (56,392)$(17,250)(d) Adjustments to interest expenseThe effect of imputed interest related to the convertible senior notes due 2016 are excluded because this expense is non-cash; such exclusion facilitates comparison of Onyx's operating results to peer companies.
4,944(e) Adjustments to other income (expenses)Impairment of equity investment in S
|SOURCE Onyx Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved